We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Beats on Q2 Earnings & Revenues, Stock Gains
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd.’s (TEVA - Free Report) shares were up 3.5% with the company announcing better-than-expected second quarter 2016 results. While earnings came in at $1.25 per share, well above the Zacks Consensus Estimate of $1.18, revenues were $5 billion, surpassing the Zacks Consensus Estimate of $4.8 billion.
While revenues were up 1% from the year-ago period, earnings declined 12.6% from the year-ago period. Currency fluctuations had a negative impact of $141 million on total revenues.
Quarter in Detail
Generic segment revenues declined 7% to $2.3 billion. Revenues from the U.S. generics business declined 33% to $892 million reflecting lower sales of the generic versions of Abilify, Nexium and Pulmicort due to loss of exclusivity.
European generic revenues continued to decline with sales coming in at $660 million, down 1% from the year-ago period.
Specialty medicines revenues grew 9% from the year-ago period to $2.3 billion reflecting higher sales of CNS (up 5% to $1.4 billion) and respiratory products (up 24% to $313 million). Oncology product sales grew 14% to $334 million while Azilect increased 3% to $108 million.
Worldwide Copaxone revenues grew 8% to $1.1 billion. While sales in the U.S. increased 10% to $955 million, ex-U.S. sales grew 1% to $186 million reflecting higher volumes in certain European and ROW markets. U.S. sales benefited from a 7.9% price increase taken in Jan 2016 as well as a reduction of sales in the Medicaid channel, resulting in both lower rebates in the current quarter and a positive change in the estimate for rebates in prior quarters.
The 40 mg thrice-weekly (3TW - three times a week) formulation accounted for 82% of total Copaxone scrips in the U.S. at the end of the reported quarter. We note that Teva is facing patent challenges for the 40 mg formulation – a trial is scheduled to commence this September with a decision expected in the first quarter of 2017.
In Jun 2015, Sandoz had launched Glatopa, its once-daily generic version of Copaxone 20 mg.
The women’s health business recorded revenues of $117 million, up 6%.
API revenues increased 13% to $207 million.
Research & Development expense increased 3.6% from the year-ago period to $370 million. Meanwhile, Selling and Marketing (S&M) expenditures grew 6.1% from the year-ago period to $898 million.
2016 Outlook Maintained
The company expects earnings of $5.20-5.40 per share on revenues $22.0-22.5 billion. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.29 billion and $5.16 per share, respectively.
Earlier this week, Teva completed its acquisition of Allergan plc’s generics business (Actavis Generics). The company also announced a deal to acquire Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million. The Anda deal is slated to close in the second half of the year.
Meanwhile, the company said that it expects to achieve $1.4 billion in operational and tax synergies from the Actavis Generics acquisition by the end of 2019. The deal is expected to boost 2017 EPS by 14% and 2019 EPS by 19%.
Our Take
Teva’s second quarter results were strong with the company beating on earnings and revenues. Strength in the specialty business helped offset weakness in the generics segment that didn’t see any major launches during the quarter. 2016 is a transition year for Teva as it works on the integration of Actavis Generics and progresses with its branded pipeline. The Actavis Generics acquisition will help the company strengthen its position in key generic markets.
Teva has also earmarked $3 billion - $4 billion for potential deals in 2016. The company is also looking to strengthen its biosimilar pipeline.
The company has quite a few important regulatory and development updates lined up this year. Investor focus will remain on the outcome of the Copaxone 40 mg patent infringement litigation.
Teva is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the healthcare sector include Anika Therapeutics Inc. (ANIK - Free Report) and Geron Corporation (GERN - Free Report) – both are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Teva (TEVA) Beats on Q2 Earnings & Revenues, Stock Gains
Teva Pharmaceutical Industries Ltd.’s (TEVA - Free Report) shares were up 3.5% with the company announcing better-than-expected second quarter 2016 results. While earnings came in at $1.25 per share, well above the Zacks Consensus Estimate of $1.18, revenues were $5 billion, surpassing the Zacks Consensus Estimate of $4.8 billion.
While revenues were up 1% from the year-ago period, earnings declined 12.6% from the year-ago period. Currency fluctuations had a negative impact of $141 million on total revenues.
Quarter in Detail
Generic segment revenues declined 7% to $2.3 billion. Revenues from the U.S. generics business declined 33% to $892 million reflecting lower sales of the generic versions of Abilify, Nexium and Pulmicort due to loss of exclusivity.
European generic revenues continued to decline with sales coming in at $660 million, down 1% from the year-ago period.
Specialty medicines revenues grew 9% from the year-ago period to $2.3 billion reflecting higher sales of CNS (up 5% to $1.4 billion) and respiratory products (up 24% to $313 million). Oncology product sales grew 14% to $334 million while Azilect increased 3% to $108 million.
Worldwide Copaxone revenues grew 8% to $1.1 billion. While sales in the U.S. increased 10% to $955 million, ex-U.S. sales grew 1% to $186 million reflecting higher volumes in certain European and ROW markets. U.S. sales benefited from a 7.9% price increase taken in Jan 2016 as well as a reduction of sales in the Medicaid channel, resulting in both lower rebates in the current quarter and a positive change in the estimate for rebates in prior quarters.
The 40 mg thrice-weekly (3TW - three times a week) formulation accounted for 82% of total Copaxone scrips in the U.S. at the end of the reported quarter. We note that Teva is facing patent challenges for the 40 mg formulation – a trial is scheduled to commence this September with a decision expected in the first quarter of 2017.
In Jun 2015, Sandoz had launched Glatopa, its once-daily generic version of Copaxone 20 mg.
The women’s health business recorded revenues of $117 million, up 6%.
API revenues increased 13% to $207 million.
Research & Development expense increased 3.6% from the year-ago period to $370 million. Meanwhile, Selling and Marketing (S&M) expenditures grew 6.1% from the year-ago period to $898 million.
2016 Outlook Maintained
The company expects earnings of $5.20-5.40 per share on revenues $22.0-22.5 billion. The Zacks Consensus Estimate for 2016 revenue and earnings are $22.29 billion and $5.16 per share, respectively.
Earlier this week, Teva completed its acquisition of Allergan plc’s generics business (Actavis Generics). The company also announced a deal to acquire Allergan’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S., for $500 million. The Anda deal is slated to close in the second half of the year.
Meanwhile, the company said that it expects to achieve $1.4 billion in operational and tax synergies from the Actavis Generics acquisition by the end of 2019. The deal is expected to boost 2017 EPS by 14% and 2019 EPS by 19%.
Our Take
Teva’s second quarter results were strong with the company beating on earnings and revenues. Strength in the specialty business helped offset weakness in the generics segment that didn’t see any major launches during the quarter. 2016 is a transition year for Teva as it works on the integration of Actavis Generics and progresses with its branded pipeline. The Actavis Generics acquisition will help the company strengthen its position in key generic markets.
Teva has also earmarked $3 billion - $4 billion for potential deals in 2016. The company is also looking to strengthen its biosimilar pipeline.
The company has quite a few important regulatory and development updates lined up this year. Investor focus will remain on the outcome of the Copaxone 40 mg patent infringement litigation.
TEVA PHARM ADR Price
TEVA PHARM ADR Price | TEVA PHARM ADR Quote
Teva is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the healthcare sector include Anika Therapeutics Inc. (ANIK - Free Report) and Geron Corporation (GERN - Free Report) – both are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>